Chen Jing-Sen, Cao Sheng-Long, Hu Hai-Ying, Shen Juan, Qi Yu-Jun
Department of Neurosurgery, The Second Affiliated Hospital, Medical School, Zhejiang University, Hangzhou, Zhejiang, China.
Department of Nutriology, The Second Affiliated Hospital, Medical School, Zhejiang University, Hangzhou, Zhejiang, China.
Des Monomers Polym. 2021 Jun 28;24(1):199-207. doi: 10.1080/15685551.2021.1935535. eCollection 2021.
In this current experiment, by applying the mixed-ligand synthesis method, two coordination polymers (CPs) containing Co(II) were created triumphantly with reaction between 1,3-bis(1-imidazoly)benzene (mbib) and Co(II) salts with the aid of diverse carboxylic ligands, and their chemical formulae are [Co(opda)(mbib)(HO)]·2HO (, Hopda is 1,2-phenylenediacetic acid) and [Co(mpda)(mbib)]·HO (, Hmpda is 1,3-phenylenediacetic acid). The two compounds' magnetic performances suggest that between the adjacent metal ions, there present the antiferromagnetic coupling. The evaluation of their treatment activity against chronic subdural hematoma was carried out and the relevant mechanism was studied simultaneously. Firstly, before the treatment of compound, the chronic subdural hematoma was generated. Furthermore, the enzyme-linked immunosorbent assay detection kit was implemented and in hematoma capsule, the anti-inflammatory cytokines level and pro-inflammatory cytokines level was detected. Additionally, the cytotoxicity of compounds and on the normal human cells was determined with Cell Counting Kit-8 assay. Above all, we proved compound decreased the pro-inflammatory cytokines content and increased the anti-inflammatory cytokines content in the hematoma capsule, which is much stronger than that of compound . Both compounds and showed no cytotoxicity on the normal human cells.
在当前的这个实验中,通过应用混合配体合成方法,借助不同的羧酸配体,1,3 - 双(1 - 咪唑基)苯(mbib)与钴(II)盐反应成功制备了两种含钴(II)的配位聚合物(CPs),它们的化学式分别为[Co(opda)(mbib)(H₂O)]·2H₂O(其中,Hopda为1,2 - 苯二甲酸)和[Co(mpda)(mbib)]·H₂O(其中,Hmpda为1,3 - 苯二甲酸)。这两种化合物的磁性能表明,相邻金属离子之间存在反铁磁耦合。同时对它们治疗慢性硬膜下血肿的活性进行了评估并研究了相关机制。首先,在化合物治疗前,制造出慢性硬膜下血肿。此外,采用酶联免疫吸附测定检测试剂盒,检测血肿包膜中抗炎细胞因子水平和促炎细胞因子水平。另外,用细胞计数试剂盒 - 8法测定化合物1和2对正常人细胞的细胞毒性。最重要的是,我们证明化合物1降低了血肿包膜中促炎细胞因子含量并增加了抗炎细胞因子含量,其效果比化合物2强得多。化合物1和2对正常人细胞均无细胞毒性。